Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Prophase Labs Inc PRPH

Healthcare
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its... see more

Recent & Breaking News (NDAQ:PRPH)

ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2023

GlobeNewswire August 10, 2023

ProPhase Labs Teams up with Certis Oncology to Accelerate Development of Novel Linebacker Compound

GlobeNewswire August 3, 2023

ProPhase Labs to Host Second Quarter 2023 Financial Results Conference Call on Thursday, August 10, 2023 at 11:00 a.m. Eastern Time

GlobeNewswire August 2, 2023

Navidea Biopharmaceuticals Rejects ProPhase Labs Offer To Acquire Certain Assets of Navidea

GlobeNewswire June 29, 2023

ProPhase Labs Inc. Sets the Course for Expansion into the MENA Region with Cutting-Edge Genomic and Diagnostics Technologies

GlobeNewswire June 22, 2023

ProPhase Labs to Present at the Diamond Equity Research Emerging Growth Invitational on Tuesday, June 13, 2023

GlobeNewswire June 7, 2023

ProPhase Labs' Cancer Therapeutic, Linebacker-1, pre-clinical studies with Dana Farber/Harvard Cancer Institute demonstrate impressive utility and move into next phase of testing

GlobeNewswire June 1, 2023

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2023

GlobeNewswire May 11, 2023

ProPhase Labs hires Dr. Matthew Halpert to Drive Company's Key Therapeutic and Diagnostic Oncology Programs

GlobeNewswire May 8, 2023

ProPhase Labs to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 11, 2023 at 11:00 a.m. Eastern Time

GlobeNewswire May 4, 2023

ProPhase Labs' Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including lung and gastric cancers

GlobeNewswire May 3, 2023

ProPhase Labs CEO Ted Karkus Named One of Inc Magazine's 10 Most Innovative Healthcare Leaders to Watch in 2023

GlobeNewswire April 28, 2023

COMSovereign Names Bill White, CFE as New Independent Director and Chair of Audit Committee

PR Newswire April 27, 2023

ProPhase Labs Announces Launch of Redesigned Corporate Website

GlobeNewswire April 25, 2023

ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & 1x1 Meetings on Thursday, April 27, 2023

GlobeNewswire April 18, 2023

ProPhase Labs Announces Record Financial Results for the year ended December 31, 2022

GlobeNewswire March 28, 2023

ProPhase Labs to Host 2022 Year End Financial Results Conference Call on Tuesday, March 28, 2023 at 11:00 a.m. Eastern Time

GlobeNewswire March 21, 2023

ProPhase Labs Announces New $6 Million Stock Repurchase Program

GlobeNewswire March 15, 2023

ProPhase Labs Announces Data Presentation for its BE-Smart Esophageal Cancer Test 

GlobeNewswire March 13, 2023

ProPhase Labs' Nebula Genomics Subsidiary Introduces Lowest Ever NGS Pricing of $249 for its Whole Genome Sequencing DNA Test

GlobeNewswire March 7, 2023